Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
Apotex Health stock: key metrics at a glance
Apotex Health (TSX:APTX) slipped about 1.3% in the latest session to CA$28.60, drawing attention to how investors might weigh its current valuation, earnings profile, and business mix across generics, biosimilars, and branded products.
See our latest analysis for Apotex Health.
The 1 day share price return of 1.35% and year to date share price return of 5.93% suggest steady but not aggressive momentum, which fits with a stock where valuation and earnings quality are central to the story.
If you are weighing Apotex Health against other pharmaceutical opportunities, it can help to see how investors are pricing growth in healthcare artificial intelligence through our 6 healthcare AI stocks
With Apotex Health trading at CA$28.60 and an estimated intrinsic discount of about 54%, the key question is whether the stock is genuinely cheap or if the market already recognizes and prices in its future growth.
Preferred P/E of 17.5x: Is it justified?
Apotex Health trades on a P/E of 17.5x, which prices the stock above the broader North American pharmaceuticals industry average of 14.7x, even though our DCF estimate suggests it is trading at a 54% discount to intrinsic value at CA$28.60.
The P/E multiple compares the current share price to earnings per share and is a quick way to see how much investors are paying for each dollar of profit. For a diversified pharmaceutical group with conventional generics, specialty generics, and brands and biosimilars across Canada, the U.S., Mexico, and India, earnings tend to be a central yardstick because many investors focus on cash generation from an established product base.
The current P/E suggests the market is willing to pay a premium over the wider North American pharmaceuticals peer group. This may reflect the recent 146.4% earnings growth and net profit margin of 10.7%. At the same time, this premium sits against a backdrop of negative shareholders’ equity and a high level of debt, which makes it harder to rely on traditional balance sheet based ratios and shifts more attention to the sustainability and quality of earnings.
Compared with the sector average of 14.7x, Apotex Health’s 17.5x P/E is materially higher, implying investors are attaching more value to its earnings than they are to the typical North American pharmaceuticals stock.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-Earnings of 17.5x (OVERVALUED).
However, this premium P/E sits alongside negative shareholders’ equity and sizeable debt, so any pressure on margins or cash flow could quickly challenge the current narrative.
